The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of March 2022. This month there are five guidelines, one and two technology appraisals that impact upon primary care.
The Mental wellbeing at work guideline has been published. It covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.
The Disabled children and young people up to 25 with severe complex needs guideline has been published. It covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
The Integrated health and social care for people experiencing homelessness guideline has been published. It covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
The Hypertension in adults: diagnosis and management guideline has been updated. It covers identifying and treating primary hypertension in people aged 18 and over, including people with type 2 diabetes. The updated includes new recommendations on blood pressure targets and antihypertensive drug treatment for people with cardiovascular disease.
The Otitis media (acute): antimicrobial prescribing guideline has been updated. It sets out an antimicrobial prescribing strategy for acute otitis media. The update adds a new recommendation on ear drops containing an anaesthetic and an analgesic because a licensed preparation is now available in the UK.
The Empagliflozin for treating chronic heart failure with reduced ejection fraction technology appraisal has been published. This treatment is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
- an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or
- sacubitril/valsartan with a beta blocker and, if tolerated, an MRA
The Dapagliflozin for treating chronic kidney disease technology appraisal has been published. This treatment is recommended as an option for treating chronic kidney disease (CKD) in adults. It is recommended only if:
- it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
- people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and:
- have type 2 diabetes or
- have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - March 2022||CKS Updates - March 2022 »|